Oligodendrocyte progenitor cells and macrophages/microglia produce glioma stem cell niche at the tumor border
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA431551 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Characterization of the tumor border microenvironment is critical for improving prognosis in patients with GBM. Here, we compared microRNA (miRNA) expression in samples from the tumor, tumor border, and peripheral region far from tumor mass by miRNA microarray. The top three of miRNAs showing higher expression in the tumor border were related to oligodendrocyte differentiation, and pathologically oligodendrocyte lineage cells were increased in the border, where numbers of macrophages and microglia also colocalized. Medium cultured with oligodendrocyte progenitor cells (OPCs) and macrophages induced stemness and chemo-radioresistance in GBM cells. Thus, OPCs and macrophages/microglia may form a glioma stem cell niche at the tumor border, representing a novel promising target for prevention of recurrence.
2018-01-26 | GSE109628 | GEO
Project description: Not available
| S-EPMC5952226 | biostudies-literature
Project description:To identify a novel miRNA that is aberrantly expressed in GICs, we analyzed differences in miRNA expression between the mouse GICs, NSCL61 and OPCL61, showing characteristic features of cancer stem cell, and their parental cells by miRNA microarrays. neural stem cells, glioma-initiating cells (GICs) from neural stem cells, oligodendrocyte precursor cells, glioma-initiating cells (GICs) from oligodendrocyte precursor cells.
2015-04-07 | E-GEOD-61080 | biostudies-arrayexpress
Project description:How malignant gliomas arise in a mature brain remains a mystery, hindering the development of preventive and therapeutic interventions. We previously showed that oligodendrocyte precursor cells (OPCs) can be transformed into glioma when mutations are introduced perinatally. However, adult OPCs rarely proliferate compared to their perinatal counterparts. Whether these relatively quiescent cells have the potential to transform is unknown, which is a critical question considering the late onset of human glioma. Additionally, the events taking place between initial mutation and a fully developed tumor mass (pre-malignant phase) are particularly poorly understood in glioma. Here we used a temporally controllable Cre transgene to delete p53 and NF1 specifically in adult OPCs, and demonstrated that these cells consistently give rise to malignant gliomas. To investigate the transforming process of quiescent adult OPCs, we then tracked these cells throughout the pre-malignant phase, which revealed a dynamic multi-step transformation, starting with rapid but transient hyper-proliferative reactivation, followed by a long period of dormancy, then final malignant transformation. Using pharmacological approaches, we discovered that mTOR signaling is critical for both the initial OPC reactivation step and late stage tumor cell proliferation, and thus might be a potential target for both glioma prevention and treatment. In summary, our results firmly establish the transforming potential of adult OPCs, and reveal an actionable multi-phasic reactivation process that turns slowly dividing OPCs into malignant gliomas. 44K Mouse Development Oligo Microarrays from Agilent Technologies were used for microarray analysis. For each experiment, total RNA was fluorescently labeled and hybridized directly against a common reference sample generated from the RNA pool of four WT P17 mouse brain neocortex.
2014-09-09 | E-GEOD-61282 | biostudies-arrayexpress
Project description:We performed gene expression profilings of platelet-derived growth factor subunit B (PDGFB)-induced mouse glioma to compare the differential transcriptome profiles between Ctrl-T tumor cells and Olig2cKO tumor cells. Expression profiling of Ctrl-T and Olig2cKO brain tumor (glioma) cells, normal oligodendrocyte progenitor cells (OPCs), normal astrocytes, and normal brain cortex by high-throughput sequencing.
2016-05-17 | E-GEOD-80087 | biostudies-arrayexpress
Project description:How malignant gliomas arise in a mature brain remains a mystery, hindering the development of preventive and therapeutic interventions. We previously showed that oligodendrocyte precursor cells (OPCs) can be transformed into glioma when mutations are introduced perinatally. However, adult OPCs rarely proliferate compared to their perinatal counterparts. Whether these relatively quiescent cells have the potential to transform is unknown, which is a critical question considering the late onset of human glioma. Additionally, the events taking place between initial mutation and a fully developed tumor mass (pre-malignant phase) are particularly poorly understood in glioma. Here we used a temporally controllable Cre transgene to delete p53 and NF1 specifically in adult OPCs, and demonstrated that these cells consistently give rise to malignant gliomas. To investigate the transforming process of quiescent adult OPCs, we then tracked these cells throughout the pre-malignant phase, which revealed a dynamic multi-step transformation, starting with rapid but transient hyper-proliferative reactivation, followed by a long period of dormancy, then final malignant transformation. Using pharmacological approaches, we discovered that mTOR signaling is critical for both the initial OPC reactivation step and late stage tumor cell proliferation, and thus might be a potential target for both glioma prevention and treatment. In summary, our results firmly establish the transforming potential of adult OPCs, and reveal an actionable multi-phasic reactivation process that turns slowly dividing OPCs into malignant gliomas.
2014-09-09 | GSE61282 | GEO
Project description:We performed genome-wide profiling of oligodendrocyte lineage transcription factor 2 (Olig2) and other histone markers in platelet-derived growth factor subunit B (PDGFB)-induced glioma and genome-occupancy analyses coupled with transcriptome profiling to reveal gene regulatory network. Examination of Olig2, H327Ac, and H3K4me3 genome-wide occupancy in PDGFB-induced Ctrl-T and Olig2cKO brain tumors (gliomas).
2016-05-17 | E-GEOD-80088 | biostudies-arrayexpress
Project description:The skull bone marrow represents a targetable neuroimmune interface adjacent to the brain borders with the potential to improve stroke outcomes. Here, we identified the skull as a highly responsive immune niche and developed a cranial photo-immunologic regulation (CPR) strategy using low-dose, narrow-band medical UVB. Targeted irradiation of the interparietal region reshapes brain border immune crosstalk, effectively promoting repair and functional recovery after ischemic injury. Mechanistically, UVB-based CPR reverses stroke-induced suppression of meningeal B cell activation, contributing to restoring brain border immune homeostasis. Depletion of meningeal B cells further demonstrates that these cells are required for the therapeutic effects of CPR. These findings establish the skull as an actionable target for neuroimmune modulation along the skull–meninges–brain axis and provide a potentially transformative strategy for treating neurological disease.
2024-04-18 | GSE252774 | GEO
Project description:The skull bone marrow represents a targetable neuroimmune interface adjacent to the brain borders with the potential to improve stroke outcomes. Here, we identified the skull as a highly responsive immune niche and developed a cranial photo-immunologic regulation (CPR) strategy using low-dose, narrow-band medical UVB. Targeted irradiation of the interparietal region reshapes brain border immune crosstalk, effectively promoting repair and functional recovery after ischemic injury. Mechanistically, UVB-based CPR reverses stroke-induced suppression of meningeal B cell activation, contributing to restoring brain border immune homeostasis. Depletion of meningeal B cells further demonstrates that these cells are required for the therapeutic effects of CPR. These findings establish the skull as an actionable target for neuroimmune modulation along the skull–meninges–brain axis and provide a potentially transformative strategy for treating neurological disease.
2024-04-18 | GSE254550 | GEO